Bioxytran, Inc.

Yahoo · Oct 19, 2026

Bioxytran Completes Production of Two Dietary Supplements: V-LO® for Immune Health and A-SUQAR® for Healthy Blood Sugar

Finished inventory of both products has been manufactured; Company is finalizing go-to-market plans Boston, MA, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT) ("Bioxytran" or the "Company"), a biotechnology company developing carbohydrate-based technologies, today announced that it has completed production of two dietary supplements: V-LO®, formulated to support normal immune function, and A-SUQAR®, formulated to support healthy post-meal blood sugar levels already within the no

Yahoo · Aug 4, 2026

Bioxytran Leverages Artificial Super Intelligence (ASI) to Design Broad-Spectrum Antiviral and Anti-Cancer Metastasis Drugs

Company's ASI-Powered Carbohydrate Design Platform, in Collaboration with University of Minnesota Department of Chemistry, Represents Paradigm Shift in Rational Drug Discovery Boston Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company pioneering innovative therapies for viral diseases and cancer metastasis, today announced the execution of a second Sponsored Research Agreement with the University of Minnesota’s Department of Chemistry to

Yahoo · Jul 29, 2026

Bioxytran Announces Publication of Corporate Research Report by Globe Small Cap Research

Report discusses ProLectin-M Phase 2 clinical results, planned 408-patient registrational trial, the BXT-25 oxygen-therapeutic platform, and Bioxytran’s A-SUQAR commercial distribution agreement BOSTON, MASSACHUSETTS, July 29, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT) (the "Company"), a clinical-stage biotechnology company developing therapeutics in based on carbohydrate chemistry, galectin antagonism, and oxygen transport, today announced the publication of a sponsored corporate re

Benzinga · Feb 11, 2026

Bioxytran Reports Phase 2 Results Showing 100% Viral Clearance By Day 7 In Randomized Double-Blind Placebo-Controlled ProLectin-M Trial (p=.001)